Skip to content

Sequential intervention of xinGengSanFang granule in patients with acute ST segment elevation myocardial infarction: a randomized, controlled, open label, multicenter clinical trial

Biological basis of pathogenesis innovation theory in different stages after myocardial infarction and intervention of traditional Chinese Medicine

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005629
Enrollment
Unknown
Registered
2022-02-09
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ST segment elevation myocardial infarction

Interventions

control group:Do not use any traditional Chinese medicine
Treatment group:sequential treatment of XinGengSanFang granules

Sponsors

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a)Aged 18 years or over and under 85 years b)Presence of STEMI who has successfully coronary recanalization by PCI within 12 h after the symptom onset; c)Willingness to provide informed consent prior to enrollment;

Exclusion criteria

Exclusion criteria: a)Blood pressure control is not ideal, systolic blood pressure exceeds 180mmHg or diastolic blood pressure exceeds 110mmHg. b)Critical condition or CPR>20 min. c)Explicit mechanical complications, including perforation of ventricular septum, rupture of papillary muscle and tendon, or rupture of left ventricular free wall. d)Uncontrolled acute left heart failure or pulmonary edema, and severe cardiogenic shock. e)Malignant arrhythmia beyond the control of antiarrhythmic drugs. f)Bleeding history of cerebrol vessels,gastrointestinal tract,respiratory tract,urinary tract,or other organs wothin 1 m. g)Presence of active hemorrhage at any part of the body(not including menstruation),and known hemorrhagic constitution or serious hemostasis and blood coagulation disorders. h)Malignant tumors or other life-threatening diseases with limited life expectancy 176.8umol/L.) n)Serious hepatic dysfunction.(ALT=5ULN)

Design outcomes

Primary

MeasureTime frame
LVEF;LVEDV;LVESV;

Countries

China

Contacts

Public ContactLI Jun
gamyylj@163.com13051458913

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026